Skip to main content

Illumina urges shareholders to reject Carl Icahn's board nominees as proxy fight heats up

Illumina told shareholders that Carl Icahn's board nominees would "threaten the progress" of the biotech company's core business.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.